Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol, Michael A. Postow, Marianne Davies, et al.
Cancer Treatment Reviews (2017) Vol. 58, pp. 70-76
Open Access | Times Cited: 266

Showing 26-50 of 266 citing articles:

Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Caroline Robert, Aurélien Marabelle, Hugo Herrscher, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 11, pp. 707-715
Closed Access | Times Cited: 82
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
Zengfu Zhang, Jialin Zhou, Vivek Verma, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes
Xuan Chen, Alison H. Affinati, Yung-Chun Lee, et al.
Diabetes Care (2022) Vol. 45, Iss. 5, pp. 1170-1176
Open Access | Times Cited: 57
Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report
Jie Zhu, Wenjie Wang
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center
Imad El Majzoub, Aiham Qdaisat, Kyaw Zin Thein, et al.
Annals of Emergency Medicine (2018) Vol. 73, Iss. 1, pp. 79-87
Open Access | Times Cited: 79
Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies
Paramarajan Piranavan, Yan Li, Edward M. Brown, et al.
The Journal of Clinical Endocrinology & Metabolism (2018) Vol. 104, Iss. 2, pp. 550-556
Open Access | Times Cited: 79
Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature
Markus Leitinger, Mihael Varosanec, Slaven Pikija, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 72
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Jay A. Fishman, John I Hogan, Marcela V. Maus
Clinical Infectious Diseases (2018) Vol. 69, Iss. 6, pp. 909-920
Closed Access | Times Cited: 69
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Arnaud Jannin, Nicolas Penel, Miriam Ladsous, et al.
Critical Reviews in Oncology/Hematology (2019) Vol. 141, pp. 23-35
Open Access | Times Cited: 65
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
Ronald Anderson, Annette J. Theron, Bernardo L. Rapoport
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 65
Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management
Jaydira Del Rivero, Lisa M. Cordes, Joanna Kłubo-Gwieździńska, et al.
The Oncologist (2019) Vol. 25, Iss. 4, pp. 290-300
Open Access | Times Cited: 64
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Virginie Lemiale, Anne‐Pascale Meert, François Vincent, et al.
Annals of Intensive Care (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 61
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
Athanasios Mavratzas, Julia Seitz, Katharina Smetanay, et al.
Future Oncology (2019) Vol. 16, Iss. 3, pp. 4439-4453
Closed Access | Times Cited: 61
<p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>
Pauline du Rusquec, Ombline de Calbiac, Marie Robert, et al.
Cancer Management and Research (2019) Vol. Volume 11, pp. 4297-4312
Open Access | Times Cited: 60
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019
Marc‐Oliver Grimm, Axel Bex, Maria De Santis, et al.
European Urology (2019) Vol. 76, Iss. 3, pp. 368-380
Open Access | Times Cited: 56
Neurological complications of cancer immunotherapy
Patrick Roth, Sebastian Winklhofer, A Müller, et al.
Cancer Treatment Reviews (2021) Vol. 97, pp. 102189-102189
Open Access | Times Cited: 56
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
Há Thi Nguyen, Komal Shah, Steven G. Waguespack, et al.
Endocrine Related Cancer (2021) Vol. 28, Iss. 7, pp. 419-431
Open Access | Times Cited: 41
Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
Raju Vaddepally, Rajiv Doddamani, Soujanya Sodavarapu, et al.
Biomedicines (2022) Vol. 10, Iss. 4, pp. 790-790
Open Access | Times Cited: 36
Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis
Qiang Su, Xiao‐Chen Zhang, Chenguang Zhang, et al.
Journal of Immunology Research (2018) Vol. 2018, pp. 1-9
Open Access | Times Cited: 53
Cancer immunotherapy-associated hypophysitis
Cinzia Solinas, Michele Porcu, Pushpamali De Silva, et al.
Seminars in Oncology (2018) Vol. 45, Iss. 3, pp. 181-186
Closed Access | Times Cited: 51
Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase
Xuefeng Bai, Xiahong Lin, Kainan Zheng, et al.
Endocrine (2020) Vol. 69, Iss. 3, pp. 670-681
Open Access | Times Cited: 48
Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist
Alexandra Lewis, Jamie E. Chaft, Monica Girotra, et al.
British Journal of Anaesthesia (2020) Vol. 124, Iss. 3, pp. 251-260
Open Access | Times Cited: 47
Management of immune related adverse events induced by immune checkpoint inhibition
Andreas Teufel, Tianzuo Zhan, Nicolai Härtel, et al.
Cancer Letters (2019) Vol. 456, pp. 80-87
Closed Access | Times Cited: 46
The Changing Clinical Spectrum of Hypophysitis
Sabrina Chiloiro, Ettore Capoluongo, Tommaso Tartaglione, et al.
Trends in Endocrinology and Metabolism (2019) Vol. 30, Iss. 9, pp. 590-602
Closed Access | Times Cited: 46
Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice
Hao Hu, Pavel Zakharov, Orion J. Peterson, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 49, pp. 31319-31330
Open Access | Times Cited: 45

Scroll to top